Published March 5, 2013 | Version v1
Journal article

What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy

  • 1. Department of Medical Physics, Hokkaido University Graduate School of Medicine, Sapporo (Japan)
  • 2. Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Kita-15Nhisi-7, , Kita-ku, Sapporo 060-8638 (Japan)

Description

We performed a dosimetric comparison of spot-scanning proton therapy (SSPT) and intensity-modulated radiation therapy (IMRT) for hepatocellular carcinoma (HCC) to investigate the impact of tumor size on the risk of radiation induced liver disease (RILD). A number of alternative plans were generated for 10 patients with HCC. The gross tumor volumes (GTV) varied from 20.1 to 2194.5 cm3. Assuming all GTVs were spherical, the nominal diameter was calculated and ranged from 3.4 to 16.1 cm. The prescription dose was 60 Gy for IMRT or 60 cobalt Gy-equivalents for SSPT with 95% planning target volume (PTV) coverage. Using IMRT and SSPT techniques, extensive comparative planning was conducted. All plans were evaluated by the risk of RILD estimated using the Lyman-normal-tissue complication probability model. For IMRT the risk of RILD increased drastically between 6.3–7.8 cm nominal diameter of GTV. When the nominal diameter of GTV was more than 6.3 cm, the average risk of RILD was 94.5% for IMRT and 6.2% for SSPT. Regarding the risk of RILD, HCC can be more safely treated with SSPT, especially if its nominal diameter is more than 6.3 cm

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-8-48; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606425

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
8
Journal Page Range
p. 48
ISSN
1748-717X

Optional Information

Copyright
Copyright (c)2013 Toramatsu et al.
Notes
PMCID: PMC3606425; PUBLISHER-ID: 1748-717X-8-48; PMID: 23497543; OAI: oai:pubmedcentral.nih.gov:3606425; licensee BioMed Central Ltd.